In the last trading session, 1.97 million Cg Oncology Inc (NASDAQ:CGON) shares changed hands as the company’s beta touched 0.96. With the company’s per share price at $26.94 changed hands at -$1.03 or -3.68% during last session, the market valuation stood at $2.05B. CGON’s last price was a discount, traded about -74.42% off its 52-week high of $46.99. The share price had its 52-week low at $14.80, which suggests the last value was 45.06% up since then. When we look at Cg Oncology Inc’s average trading volume, we note the 10-day average is 2.12 million shares, with the 3-month average coming to 1.02 million.
Analysts gave the Cg Oncology Inc (CGON) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CGON as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Cg Oncology Inc’s EPS for the current quarter is expected to be -0.34.
Cg Oncology Inc (NASDAQ:CGON) trade information
Instantly CGON was in red as seen at the end of in last trading. With action 31.54%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -6.07%, with the 5-day performance at 31.54% in the green. However, in the 30-day time frame, Cg Oncology Inc (NASDAQ:CGON) is 1.97% up. Looking at the short shares, we see there were 9.09 million shares sold at short interest cover period of 7.2 days.
The consensus price target for the stock as assigned by Wall Street analysts is 55, meaning bulls need an upside of 51.02% from its current market value. According to analyst projections, CGON’s forecast low is 55 with 55 as the target high. To hit the forecast high, the stock’s price needs a -104.16% plunge from its current level, while the stock would need to soar -104.16% for it to hit the projected low.
Cg Oncology Inc (CGON) estimates and forecasts
Year-over-year growth is forecast to reach 177.87% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 144.61k. 6 analysts are of the opinion that Cg Oncology Inc’s revenue for the current quarter will be 148.78k. The company’s revenue for the corresponding quarters a year ago was 529k and 111k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -72.66%. The estimates for the next quarter sales put growth at 34.04%.
The 2025 estimates are for Cg Oncology Inc earnings to decrease by -26.26%, but the outlook for the next 5-year period is at 31.21% per year.
CGON Dividends
Cg Oncology Inc is expected to release its next quarterly earnings report on 2025-Mar-27.
Cg Oncology Inc (NASDAQ:CGON)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.16% of Cg Oncology Inc shares while 98.39% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 104.85%. There are 98.39% institutions holding the Cg Oncology Inc stock share, with DECHENG CAPITAL LLC the top institutional holder. As of 2024-06-30, the company held 8.1903% of the shares, roughly 5.46 million CGON shares worth $172.33 million.
TCG CROSSOVER MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 5.5067% or 3.67 million shares worth $115.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . With 1.89 shares estimated at $50.82 million under it, the former controlled 2.48% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund held about 2.05% of the shares, roughly 1.56 shares worth around $42.03 million.
